Canadian Cohort
Obstructive Lung Disease
since 2009
CanCOLD participants completed visit 4
and trainees in Canada and abroad with a rich and
invaluable resource for COPD research.
MORE BREADTH FOR A NEW BREATH
CanCOLD is a collaborative Canadian-wide study advancing our knowledge of why people develop COPD, how and why COPD impacts individuals differently, and how we can better care for people affected by this disease
Who We Are
The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is a longitudinal study following 1,500 participants in Canada since 2009. CanCOLD aims to enhance the current understanding of COPD progression and burden, and to better advance COPD prevention, diagnosis and management. Public and private investments of more than $14,000,000 have allowed the CanCOLD study to produce policy-relevant knowledge and innovative solutions that have positive impacts on public health and clinical practice. CanCOLD leverages partnerships between researchers and organizations, and also provides opportunities for graduate students to be trained and young investigators to participate in innovative respiratory health research projects in many institutions across Canada.
What is COPD?
COPD (Chronic Obstructive Pulmonary Disease) is a group of diseases including emphysema, chronic bronchitis and non-reversible asthma. COPD results in inflammation and partial blocking of the airways (breathing tubes) in an individual’s lungs, thereby making breathing difficult.
COPD is a long-term disease that tends to get worse over time, and significantly impacts an individual’s health and autonomy. In Canada, 2 million people are living with COPD, a major cause of disability and one of the leading causes of deaths.
3rd
leading cause of death
worldwide
1 st
cause of hospitalization
in Canada
$4 billion
in direct and indirect costs
annually in Canada